UNITED THERAPEUTICS Corp
United Therapeutics Corporation (Nasdaq: UTHR) develops and sells therapies for serious diseases, primarily pulmonary arterial hypertension (PAH), and is developing technologies to expand the supply of transplantable organs. Its marketed products include treprostinil therapies Tyvaso DPI, Nebulized Tyvaso, Remodulin… From the company’s description.
In fiscal 2025, UNITED THERAPEUTICS Corp reported revenue of $3.18B, up 10.6% from fiscal 2024, and net income of $1.33B. Its operating margin was 46.9%, and operations generated $1.56B in cash. Over the twelve months to Jun 30, 2026, revenue was $3.15B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What UNITED THERAPEUTICS Corp does
In the company’s own words
United Therapeutics Corporation (Nasdaq: UTHR) develops and sells therapies for serious diseases, primarily pulmonary arterial hypertension (PAH), and is developing technologies to expand the supply of transplantable organs. Its marketed products include treprostinil therapies Tyvaso DPI, Nebulized Tyvaso, Remodulin and Orenitram, as well as Adcirca for PAH, Unituxin for high-risk neuroblastoma, and pumps for delivering Remodulin. Tyvaso DPI and Nebulized Tyvaso are also approved for pulmonary hypertension associated with interstitial lung disease. The company sells its products through specialty pharmaceutical distributors and serves patients, prescribers and transplant centers. Its research includes drug candidates for pulmonary fibrosis and PAH, gene-edited pig organs for xenotransplantation, engineered organ alternatives and lung-perfusion services. United Therapeutics operates as a public benefit corporation and has acquired regenerative-medicine businesses Miromatrix and IVIVA. Tyvaso DPI and Nebulized Tyvaso together generated $1.88 billion, or 59% of revenue, in 2025; total revenue was approximately $3.2 billion that year. Its website is www.unither.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SILVER SPRING, MD
- Fiscal year end
- December
- CIK
- 1082554
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns UNITED THERAPEUTICS Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · UNITED THERAPEUTICS Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do UNITED THERAPEUTICS Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of UNITED THERAPEUTICS Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in UNITED THERAPEUTICS Corp's last four quarterly filings that the numbers alone won't show?”